Supporting the quality of life of elderly dogs through evidence-based care
Dogs are living longer than ever due to improved veterinary care and nutrition. The average UK dog now lives to 12-13 years; giant breeds 8-10 years; small breeds 14-16 years. This aging population faces specific welfare challenges: osteoarthritis (affecting 20-80% of dogs over 8), cognitive dysfunction syndrome (affecting 25-68% of dogs over 11), sensory decline, and reduced quality of life. Evidence-based geriatric care can dramatically improve welfare in the final years of dog life.
Canine Cognitive Dysfunction Syndrome (CDS) is the dog equivalent of Alzheimer's disease. Affected dogs show progressive neurological deterioration causing disorientation, anxiety, and loss of learned behaviors. Welfare impact is significant: dogs may be confused and frightened. Evidence-based management: selegiline (MAO-B inhibitor), dietary supplementation (omega-3, antioxidants), environmental enrichment to maintain cognitive engagement, and nighttime management for sleep disruption.
Osteoarthritis is endemic in older dogs but chronically underdiagnosed — owners often attribute reduced activity to "old age" rather than pain. Multimodal pain management has transformed welfare outcomes: long-acting NSAIDs (meloxicam, carprofen), gabapentin, tramadol, and increasingly monoclonal antibody treatments (frunevetmab) targeting nerve growth factor. Quality of life monitoring tools (Helsinki Chronic Pain Index, Canine Brief Pain Inventory) enable objective tracking of pain management effectiveness.